EGFR and non-small cell lung carcinoma: Therefore, this study focused on defining the molecular mechanisms by which TRPM2 expression is suppressed by osimertinib and its involvement in mediating therapeutic efficacy of osimertinib against EGFRm NSCLC via testing the overall hypothesis that effective inhibition of TRPM2 expression is an essential event in maintaining long‐term therapeutic efficacy of osimertinib or other 3rd generation EGFR‐TKIs in the treatment of EGFRm NSCLCs.